DiagnoCure Licenses Colorectal Cancer ASRs From TDT

May 02, 2007

NEW YORK (GenomeWeb News) — DiagnoCure said yesterday that it plans to develop and sell two molecular diagnostic tests for cancer that it licensed from Targeted Diagnostics and Therapeutics.

DiagnoCure said the tests are designed to detect guanylyl cyclase C, or GCC. The company said the GCC gene appears normally in cells lining the intestines, but has only been found outside the intestine when colorectal cancer has metastasized.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Main menu